GeoVax Labs (GOVX) Competitors

$1.67 -0.09 (-5.11%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$1.62 -0.04 (-2.69%)

As of 05/8/2026 07:59 PM Eastern

GOVX vs. PHIO, LIAN, FNCH, BIVI, and BFRI

Should you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include Phio Pharmaceuticals (PHIO), LianBio (LIAN), Finch Therapeutics Group (FNCH), BioVie (BIVI), and Biofrontera (BFRI). These companies are all part of the "pharmaceutical products" industry.

How does GeoVax Labs compare to Phio Pharmaceuticals?

GeoVax Labs (NASDAQ:GOVX) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 1 mentions for GeoVax Labs. Phio Pharmaceuticals' average media sentiment score of 0.36 beat GeoVax Labs' score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GeoVax Labs currently has a consensus target price of $150.00, suggesting a potential upside of 8,882.04%. Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,208.41%. Given GeoVax Labs' higher probable upside, research analysts clearly believe GeoVax Labs is more favorable than Phio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

GeoVax Labs has a beta of 3.36, meaning that its share price is 236% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 0.6% of GeoVax Labs shares are held by insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Phio Pharmaceuticals' return on equity of -66.59% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-441.42%	-293.48%
Phio Pharmaceuticals	N/A	-66.59%	-60.26%

Phio Pharmaceuticals has lower revenue, but higher earnings than GeoVax Labs. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.94	-$21.47M	-$35.25	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.45	N/A

Summary

Phio Pharmaceuticals beats GeoVax Labs on 10 of the 14 factors compared between the two stocks.

How does GeoVax Labs compare to LianBio?

GeoVax Labs (NASDAQ:GOVX) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

In the previous week, GeoVax Labs had 1 more articles in the media than LianBio. MarketBeat recorded 1 mentions for GeoVax Labs and 0 mentions for LianBio. GeoVax Labs' average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.

Company	Overall Sentiment
GeoVax Labs	Neutral
LianBio	Neutral

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 0.6% of GeoVax Labs shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

GeoVax Labs has higher revenue and earnings than LianBio. LianBio is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.94	-$21.47M	-$35.25	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

GeoVax Labs has a beta of 3.36, indicating that its stock price is 236% more volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.

GeoVax Labs presently has a consensus target price of $150.00, indicating a potential upside of 8,882.04%. Given GeoVax Labs' stronger consensus rating and higher probable upside, equities analysts plainly believe GeoVax Labs is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

LianBio's return on equity of -33.17% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-441.42%	-293.48%
LianBio	N/A	-33.17%	-30.19%

Summary

GeoVax Labs beats LianBio on 7 of the 12 factors compared between the two stocks.

How does GeoVax Labs compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

In the previous week, GeoVax Labs had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for GeoVax Labs and 0 mentions for Finch Therapeutics Group. Finch Therapeutics Group's average media sentiment score of 0.00 equaled GeoVax Labs'average media sentiment score.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
GeoVax Labs	Neutral

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 8,882.04%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 0.6% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

GeoVax Labs has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
GeoVax Labs	$2.49M	1.94	-$21.47M	-$35.25	N/A

Finch Therapeutics Group has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.36, indicating that its stock price is 236% more volatile than the S&P 500.

Finch Therapeutics Group's return on equity of -69.14% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
GeoVax Labs	N/A	-441.42%	-293.48%

Summary

GeoVax Labs beats Finch Therapeutics Group on 7 of the 12 factors compared between the two stocks.

How does GeoVax Labs compare to BioVie?

BioVie (NASDAQ:BIVI) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 8,882.04%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

BioVie has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.36, indicating that its share price is 236% more volatile than the S&P 500.

BioVie has higher earnings, but lower revenue than GeoVax Labs. BioVie is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$3.25	N/A
GeoVax Labs	$2.49M	1.94	-$21.47M	-$35.25	N/A

BioVie's return on equity of -82.09% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-82.09%	-73.04%
GeoVax Labs	N/A	-441.42%	-293.48%

In the previous week, BioVie had 2 more articles in the media than GeoVax Labs. MarketBeat recorded 3 mentions for BioVie and 1 mentions for GeoVax Labs. BioVie's average media sentiment score of 0.33 beat GeoVax Labs' score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.6% of BioVie shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 0.9% of BioVie shares are held by company insiders. Comparatively, 0.6% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

BioVie beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.

How does GeoVax Labs compare to Biofrontera?

GeoVax Labs (NASDAQ:GOVX) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Biofrontera has higher revenue and earnings than GeoVax Labs. Biofrontera is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.94	-$21.47M	-$35.25	N/A
Biofrontera	$41.71M	0.33	-$10.54M	-$1.03	N/A

GeoVax Labs has a beta of 3.36, suggesting that its share price is 236% more volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.

In the previous week, Biofrontera had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GeoVax Labs has a net margin of 0.00% compared to Biofrontera's net margin of -25.26%. GeoVax Labs' return on equity of -441.42% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-441.42%	-293.48%
Biofrontera	-25.26%	-1,236.11%	-56.67%

GeoVax Labs currently has a consensus price target of $150.00, suggesting a potential upside of 8,882.04%. Biofrontera has a consensus price target of $2.75, suggesting a potential upside of 139.13%. Given GeoVax Labs' higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 0.6% of GeoVax Labs shares are held by insiders. Comparatively, 4.8% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Biofrontera beats GeoVax Labs on 9 of the 15 factors compared between the two stocks.

Get GeoVax Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOVX vs. The Competition

Export

Metric	GeoVax Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.83M	$3.39B	$6.35B	$12.32B
Dividend Yield	N/A	2.26%	2.78%	5.22%
P/E Ratio	-0.05	15.62	21.18	25.42
Price / Sales	1.94	316.30	543.70	84.24
Price / Cash	N/A	122.48	43.07	53.89
Price / Book	0.76	7.32	9.97	6.83
Net Income	-$21.47M	$24.23M	$3.55B	$333.46M
7 Day Performance	45.22%	2.21%	3.50%	3.08%
1 Month Performance	35.77%	5.78%	4.89%	7.52%
1 Year Performance	-92.80%	78.95%	41.93%	41.50%

GeoVax Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOVX GeoVax Labs	1.7295 of 5 stars	$1.67 -5.1%	$150.00 +8,882.0%	-92.8%	$4.83M	$2.49M	N/A	10
PHIO Phio Pharmaceuticals	3.2324 of 5 stars	$1.16 +1.8%	$14.00 +1,106.9%	-39.5%	$13.24M	N/A	N/A	10	News Coverage Earnings Report
LIAN LianBio	N/A	$0.12 -0.4%	N/A	N/A	$13.13M	N/A	N/A	110
FNCH Finch Therapeutics Group	N/A	$8.15 +12.7%	N/A	-39.3%	$13.09M	N/A	N/A	190	Gap Down
BIVI BioVie	1.0461 of 5 stars	$1.72 +2.4%	N/A	-86.8%	$12.67M	N/A	N/A	10	News Coverage Upcoming Earnings High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOVX) was last updated on 5/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeoVax Labs (GOVX) Competitors

GOVX vs. PHIO, LIAN, FNCH, BIVI, and BFRI

How does GeoVax Labs compare to Phio Pharmaceuticals?

Summary

How does GeoVax Labs compare to LianBio?

Summary

How does GeoVax Labs compare to Finch Therapeutics Group?

Summary

How does GeoVax Labs compare to BioVie?

Summary

How does GeoVax Labs compare to Biofrontera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GeoVax Labs (GOVX) Competitors

GOVX vs. PHIO, LIAN, FNCH, BIVI, and BFRI

How does GeoVax Labs compare to Phio Pharmaceuticals?

Does the media refer more to GOVX or PHIO?

Do analysts recommend GOVX or PHIO?

Which has more risk and volatility, GOVX or PHIO?

Do institutionals and insiders hold more shares of GOVX or PHIO?

Is GOVX or PHIO more profitable?

Which has stronger valuation & earnings, GOVX or PHIO?

Summary

How does GeoVax Labs compare to LianBio?

Does the media favor GOVX or LIAN?

Do insiders and institutionals believe in GOVX or LIAN?

Which has stronger earnings and valuation, GOVX or LIAN?

Which has more risk & volatility, GOVX or LIAN?

Do analysts recommend GOVX or LIAN?

Is GOVX or LIAN more profitable?

Summary

How does GeoVax Labs compare to Finch Therapeutics Group?

Does the media prefer FNCH or GOVX?

Do analysts rate FNCH or GOVX?

Do institutionals & insiders have more ownership in FNCH or GOVX?

Which has preferable valuation and earnings, FNCH or GOVX?

Which has more risk and volatility, FNCH or GOVX?

Is FNCH or GOVX more profitable?

Summary

How does GeoVax Labs compare to BioVie?

Do analysts rate BIVI or GOVX?

Which has more volatility & risk, BIVI or GOVX?

Which has preferable earnings & valuation, BIVI or GOVX?

Is BIVI or GOVX more profitable?

Does the media refer more to BIVI or GOVX?

Do insiders & institutionals have more ownership in BIVI or GOVX?

Summary

How does GeoVax Labs compare to Biofrontera?

Which has better valuation & earnings, GOVX or BFRI?

Which has more volatility and risk, GOVX or BFRI?

Does the media prefer GOVX or BFRI?

Is GOVX or BFRI more profitable?

Do analysts prefer GOVX or BFRI?

Do insiders and institutionals have more ownership in GOVX or BFRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools